Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer [0.03%]
NCI临床试验计划会议关于非肌层浸润性膀胱癌新一代临床试验的摘要
Andrea Apolo,Brian C Baumann,Hikmat Al-Ahmadie et al.
Andrea Apolo et al.
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cance...
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer [0.03%]
DNA修复缺陷对膀胱癌中抗体药物偶联物(ADC)负载敏感性的影响研究
Surish P Shanmugam,Yuzhen Zhou,Isabella Stelter et al.
Surish P Shanmugam et al.
Background: Enfortumab vedotin (EV) and Sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) with demonstrated activity in advanced bladder cancer. A subset of bladder tumors harbors a DNA repair deficiency in e...
Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer [0.03%]
膀胱癌新辅助ddMVAC化疗中传统顺铂与分次顺铂的用药模式及预后
Eryn B Callihan,Elizabeth Molina Kuna,Corbin J Eule et al.
Eryn B Callihan et al.
Background: The practice patterns and efficacy of ddMVAC administered with split-dose cisplatin for patients with muscle-invasive bladder cancer (MIBC) remains largely undefined. ...
Edward M Messing
Edward M Messing
Mark S Soloway,Neil A Abrahams,Nat Pinnar
Mark S Soloway
Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists [0.03%]
荷兰泌尿科医师对膀胱癌患者的生话方式指导建议全国调查
Ivy Beeren,Carlos Koops,Antoine G van der Heijden et al.
Ivy Beeren et al.
Background: Not much is known about the extent to which urologists discuss lifestyle with patients with bladder cancer (BC), despite patients considering urologists as an important source of information and motivation. ...
Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now [0.03%]
ctDNA指导尿路上皮癌手术治疗的未来已来
Tyler F Stewart,Healther Chalfin,Nicholas Simon et al.
Tyler F Stewart et al.
Muscle-invasive bladder cancer represents a potentially curable disease, yet often disease recurs and is ultimately fatal. Outcomes for patients with localized urothelial carcinoma are heterogeneous with some patients cured with surgery alo...
A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer [0.03%]
高危非肌层浸润性膀胱癌监测期间检测复发的分子尿检试验
Joep J de Jong,Florus C de Jong,Angelique C J van der Made et al.
Joep J de Jong et al.
Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients require long-term surveillance with cystoscopies, cytology and upper tract imaging. Previously, we developed a genomic urine assay for surveilla...
Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial [0.03%]
延长抗生素预防用药在根治性膀胱切除术中有效性的实效性研究：MACS随机临床试验的初步分析
Mariya Vladimirovna Berkut,Alexey Michaylovich Belyaev,Tatyana Yurievna Galunova et al.
Mariya Vladimirovna Berkut et al.
Background: Standard 24-hour antibiotic prophylaxis is widely employed to minimize the risk of infection complications within 30 days following radical cystectomy. However, a considerable variety of protocols and drug com...
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer [0.03%]
膀胱癌三联疗法临床试验的入组条件和终点指标选择标准
Parminder Singh,Leslie Ballas,Guru P Sonpavde et al.
Parminder Singh et al.
Background: Trimodality therapy (TMT) is a viable option for muscle-invasive localized bladder cancer, providing an alternative to radical cystectomy in properly selected patients. The approval of novel therapeutics in di...